Articles tagged with Drug Discovery
Surzen Biotherapeutics aims to develop effective pain relief without severe side effects by targeting opioid receptor pathways differently. The company plans to use peptides to block dimerization, reducing tolerance and improving efficacy.
Researchers developed a new molecular editing strategy that relocates the nitrogen atom within the pyridine ring, creating positional isomers. This approach preserves substituents while altering properties such as solubility and interactions with biological targets.
Researchers from the University of Rochester's TraCe-bMPS have developed tissue chips that can predict dangerous immune reactions to cancer therapies. The technology, which uses human cells and sensors, has been accepted into the FDA's Innovative Science and Technology Approaches for New Drugs pilot program.
The new integrations provide enterprise AI agents direct access to live, structured research data from Dimensions' 430M+ interconnected records. This allows for AI-assisted analytics across one of the world's most comprehensive linked views of global research activity.
Researchers have found a new compound that promotes joint health and reduces inflammation-related genes in a model of osteoarthritis. The drug, M04, has shown promise as an innovative OA therapy by slowing down the disease process, giving people more years of pain-free living.
Researchers created nearly 700 new cancer models derived from patient tumors to aid in drug development. The models, representing 25 types of cancer, are now available for global use, providing a resource for identifying new drug targets and testing potential treatments.
Scientists at Gladstone Institutes have developed a regenerative treatment using stem cell-derived spinal interneurons to repair damaged neural networks in rats. The new cells not only survived and formed connections with the animals' own neural circuits but also improved breathing-related motor function after transplantation.
A study at USC discovers a common genetic variant in Indigenous American populations that silences the microprotein MENTSH, restoring it improves insulin signaling and blocks diet-induced weight gain. MENTSH-based therapies could offer a precision-medicine approach to Type 2 diabetes.
Researchers found that even losing one copy of the TBX5 gene can drastically derail heart development due to DNA misfolding. The study reveals a new origin for genetic disease, suggesting that small drops in protein levels can scramble the 3D structure of DNA.
Revolver Therapeutics, a spin-out company from the University of Bath, has won the Health category of the Royal Society of Chemistry's Emerging Technologies Competition with its proprietary discovery platform. The platform generates and tests millions of constrained peptide drug candidates directly inside living cells, selecting for mo...
A review study reveals diverse metabolite families containing atypical atoms, including fluorine, selenium, arsenic, and boron, with distinct biological functions and properties. These elements shape natural products with structural and functional versatility, paving ways toward sustainable biotechnologies.
Researchers have identified a widespread source of error in a popular genome study method and created a machine-learning tool to correct it. PATTY uses machine learning to reduce artifacts while preserving real signals in noisy data, giving researchers a clearer view of gene activity control.
SLAS Discovery highlights innovative screening platforms accelerating therapeutic discovery for neurodegenerative diseases, including a newly identified link to Alzheimer's progression. The journal showcases novel technologies and approaches to understand and treat human disease, advancing life sciences discovery and technology.
This volume of SLAS Technology highlights novel laboratory technologies, open-source software, and disease-specific tools for advancing life sciences research and development. The journal emphasizes the importance of education, knowledge exchange, and global community building to drive innovation in biomedical research.
Researchers at Texas A&M University have found a way to intervene early in traumatic brain injuries using a natural, gut-derived chemical that prevents post-traumatic epilepsy from taking root. The treatment reduced brain inflammation, improved memory and mood, protected brain cells, made seizures both rarer and harder to trigger.
Deep learning models accelerate drug design, predict chemical interactions, and engineer stable candidates. AI-powered simulations optimize dosimetry, predicting biodistribution and generating patient-specific digital twins for individualized treatment planning.
Scientists at King's College London have developed a human-safe drug that repairs DNA breaks and reduces inflammation in a mouse model of Alzheimer's disease. This approach targets multiple features of the disease simultaneously, providing a broader therapeutic strategy than previous approaches focused on individual disease hallmarks.
Researchers developed a human-safe drug that repairs DNA breaks and reduces inflammation in a mouse model of Alzheimer's disease. The approach targets multiple disease-relevant cellular pathways, providing a broader therapeutic strategy than previous approaches focused on individual disease hallmarks.
Researchers discovered a potential drug developed at Michigan Medicine reverses metabolic dysfunction-associated steatohepatitis (MASH) in animal models by disrupting the disease-driving pathway that links the gut and liver. DT-109 improved gut health, reducing inflammation in livers of nonhuman primates.
BetaDescribe, an AI system, converts protein sequences into detailed textual descriptions of their functions and characteristics. The technology helps bridge the gap between characterized and existing proteins in nature, enabling researchers to rapidly generate evidence-based hypotheses regarding unknown proteins.
A team of researchers has developed a new method for finding effective tuberculosis drugs by leveraging the PAC-MAN technique and artificial intelligence. The approach uses machine learning models to predict which chemical compounds can penetrate the outer membrane of the bacteria, paving the way for more efficient drug discovery.
A USC interdisciplinary team has identified a promising pathway to turn off brain inflammation before it does its damage, increasing the risk of late-onset Alzheimer's. The Norman and Mary Pattiz Foundation funding will support research on novel drug discovery, early detection, and prevention of Alzheimer's disease.
A team from the University of Osaka has created a high-throughput platform to engineer versatile biosensors that can track lipid molecules in living cells. This method, called Cell surface Liposome Binding (CLiB) assay, uses yeast cells and fluorescence readouts to test protein variants' binding to lipids.
Researchers at Texas A&M University develop a laser technique called TRIP to directly measure quantum forces shaping proteins, enabling accurate prediction of how pharmaceutical drugs interact with them. This breakthrough could lead to the design of medicines tailored to specific diseases, revolutionizing precision medicine.
A POSTECH research team has created an automated, modular system for assembling reconstituted cell-free systems, significantly reducing costs by 95% and preparation time to 2 days. This innovation enables the customization of individual components, paving the way for improved biologically engineered high-value therapeutics.
Researchers develop cellular model to reproduce NF1-associated tumour progression, identifying new therapeutic opportunities. The combination of olaparib and selumetinib shows promise in reducing tumour growth.
Researchers at Purdue University have developed a next-generation technology platform designed to dramatically accelerate one of the slowest stages of cancer drug discovery. The platform combines chemical synthesis, biological testing, and mass spectrometry into a single integrated workflow, allowing researchers to generate, evaluate, ...
Universities and hospitals conduct substantial numbers of late-stage clinical trials to repurpose generic drugs at reduced costs. This research has huge potential to provide society with affordable treatments for various conditions.
The International Society for Stem Cell Research announces the launch of a global consortium focused on integrating human stem cell-derived models into preclinical drug development. Bayer is a founding member, aiming to establish standardized frameworks and regulatory guidance for these models.
Terasaki Institute researchers and key pioneers publish comprehensive review on glioma organoid models, proposing a foundational classification framework to guide translational brain tumor research. The review provides an overview of human glioma organoid systems and aims to address methodological heterogeneity in the field.
The University of Virginia has joined SPARK GLOBAL to leverage resources and expertise in accelerating the development of new medicines. This collaboration aims to reduce time from lab discoveries to clinic trials, delivering tangible healthcare solutions to patients.
A large-scale Phase 3 trial of CRISPR therapy has shown an 87% reduction in attacks for patients with hereditary angioedema. The treatment also improved quality-of-life scores and reduced the need for on-demand medication, paving the way for future genetic therapies.
Physicists at UC Berkeley introduce phase contrast to electron microscopy, enabling clearer images of small molecules and structures inside cells. The laser phase plate enhances cryoelectron microscopy, overcoming signal-to-noise limitations and paving the way for new drug discovery.
Scripps Research team creates stereoretentive radical-radical cross-coupling, a simpler way to build chiral drug candidates while maintaining 3D structure. The new reaction uses a nickel catalyst and produces practical yields with high enantiospecificity.
The Acceleration Consortium and Structural Genomics Consortium collaborate to develop new drugs using AI-driven lab capabilities. The partnership aims to speed up the discovery of bioactive molecules, advancing human health and disease understanding.
Researchers summarize recent developments in terahertz biophotonics, highlighting its potential for overcoming technical limitations in fields like skin cancer diagnosis, wound assessment, and drug discovery. The study provides a roadmap for future research to improve the field's practical applications.
Researchers at IRB Barcelona used AI to design new chemical entities that selectively target specific cell types, demonstrating superior activity compared to conventional screening strategies. The methodology, called phenotypic discovery, uses observable responses in cells rather than a specific molecular target.
Andrew Yang's research has reshaped scientific understanding of the blood-brain barrier and its role in brain health and disease. His latest study reveals new potential treatment targets for neurological diseases, normal aging, and sleep.
Researchers at King's College London have developed a new approach called 'Efflux Resistance Breaker' (ERB), designed to overcome one way bacteria escape antibiotic treatment. This allows antibiotics to remain inside bacterial cells at higher concentrations, restoring their ability to kill bacteria even with resistance mechanisms present.
Researchers are using 3D cardiac constructs to model cardiovascular diseases and test new drugs. These constructs can capture the complexity of human cardiac tissue, including its electrical activity, metabolism, and cellular communication. The field is advancing with biomaterials, AI-assisted screening, and improved standardization.
Two projects, BOOST-HP and BIONIC, use machine learning to analyze large datasets of medication exposure and outcomes. The findings highlight the need for more data and cautious design of machine learning models to accurately assess potential links between medications and pregnant women.
Researchers at Memorial Sloan Kettering Cancer Center have uncovered promising combination therapies for a rare childhood brain tumor by analyzing patient samples, cell models, and laboratory data. The study found that cancer cells can develop workarounds to evade targeted RAS therapies, highlighting the need for new treatment strategies.
The coalition aims to accelerate validation and qualification of human-relevant methodologies, such as complex in vitro models and microphysiological systems, for drug discovery and development. By aligning developers around shared qualification standards, the coalition reduces duplicative validation efforts and helps regulators evalua...
The ISSCR Consortium supports the FDA's draft guidance on using new approach methodologies (NAMs) in drug development, emphasizing the need for a flexible and science-driven framework. The consortium recommends clarifying biological complexity alignment with context of use and expanding recognition of computational modeling and hybrid ...
Researchers from Harrington Discovery Institute provide a new understanding of cancer processes and identify promising targets for treatments. They uncover a class of therapeutic targets that may complement existing therapies.
Researchers found that Rhein reduces pancreatic and intestinal damage, restores intestinal barrier integrity, and promotes repair macrophage responses. PPARγ is identified as the central mediator of Rhein's effects.
Researchers developed ApexGO, an AI-powered method to turn weak antibiotic candidates into more potent ones. The tool uses generative AI and Bayesian optimization to guide molecular tweaks, predicting which changes are likely to increase antimicrobial activity.
Researchers developed genESOM, a generative AI that can expand dataset volume and simulate larger animal numbers while maintaining reliability. This allows for 30-50% reduction in animal experiments without compromising results.
A new framework aims to embed natural laws, scientific goals, and ethical standards into AI-driven molecular design processes. This requires addressing misalignment between AI objectives and real-world scientific and societal requirements.
A team of researchers has uncovered a promising new target for antimalarial drug design, identifying an enzyme called aminopeptidase P from the Plasmodium falciparum parasite. The new inhibitors have been shown to bind more strongly and selectively than existing compounds, demonstrating potential as a new class of drugs to combat malaria.
The UK-led OpenBind initiative has released its first publicly available dataset and predictive AI model, accelerating the discovery of new medicines using artificial intelligence. The release showcases high-quality, standardized experimental data and a trained predictive model, enabling researchers worldwide to drive the next generati...
A new study published in Science Advances identifies IRS4 as a promising drug target for multiple solid tumors, offering hope for safer cancer treatments. By using AI and natural mutations, researchers prioritized targets with high therapeutic indexes to minimize toxicity.
Researchers have identified a gene, eIF4G2, crucial for keeping adult intestinal stem cells stable and functional. The study reveals that the gene plays a vital role in regulating protein production and maintaining stem cell identity.
Researchers used a new AI-powered computational method to discover that most nucleosomes contain sections of DNA that are partially accessible to the cell. The study found that more than 85% of nucleosomes showed some degree of distortion, with 14 distinct structural states associated with different levels of gene activity.
A UCLA-led international collaboration has unveiled a new technology that enables scientists to directly compare how different molecules compete for the same binding site on a protein, all in a single experiment. The results show promising interactions between two cancer drugs and reveal previously unknown interactions.
Researchers at the University of East Anglia have discovered that light can be programmed using its natural geometry, allowing for the creation of structured light with unique properties. This breakthrough has far-reaching implications for fields such as medicine, data transmission, and quantum technologies.
The kinase field offers significant therapeutic opportunities, with many understudied kinases waiting to be explored. Recent advances in chemical probe development and resource availability have led to a shift towards more systematic exploration of previously neglected targets.
Researchers at the University of British Columbia have developed a new method to target intrinsically disordered proteins, which are difficult to treat with medication. The approach has shown promise in slowing prostate cancer growth and could lead to new treatments for various diseases.
A computational protocol has been established by University of Kent researchers to accurately identify reactions that can result in successful drug candidates for Chagas disease. This approach reduces the need for trial-and-error, prioritizing promising compounds earlier and making the drug discovery process faster and more affordable.
Dr. Dennis Slamon, a renowned breast cancer researcher, has been elected to the Association of American Physicians (AAP) for his pioneering work in HER2 gene discovery and targeted therapies. His research led to significant improvements in survival rates and established the principle of targeted cancer treatment.